Anika (ANIK) Q2 Revenue Beats by 4%
Anika Therapeutics (NASDAQ:ANIK), a medical technology company focused on joint preservation and regenerative therapy products, released its earnings on July 30, 2025. The key news from the release was that while the company outperformed revenue estimates—reporting $28.2 million (GAAP) compared to the expected $27.03 million—profitability came under pressure, with a larger loss versus last year. The non-GAAP loss was $(0.13), markedly below last year’s $0.04 profit. The quarter’s overall assessment points to operational progress in core product areas and cost controls, but structural headwinds in pricing and inventory dynamics weighed on bottom-line results.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Anika Therapeutics develops and manufactures medical products using hyaluronic acid (HA), a naturally occurring molecule that aids in lubrication and tissue healing. Its main product families target osteoarthritis (OA) pain management and regenerative solutions for soft tissue repair. Key products include Monovisc and Orthovisc for OA pain, and Integrity, a tendon augmentation implant, within the regenerative segment.
Source Fool.com
Anika Therapeutics Stock
We see a rather positive sentiment for Anika Therapeutics with 8 Buy predictions and 1 Sell predictions.
With a target price of 18 € there is potential for a 150.0% increase which would mean more than doubling the current price of 7.2 € for Anika Therapeutics.
